Sydnexis, Inc. Advances SYD-101 Data in Myopia Trial
DEL MAR, California, May 1, 2026 Sydnexis, Inc. announced it will present new Phase 3 STAR trial data for...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
DEL MAR, California, May 1, 2026 Sydnexis, Inc. announced it will present new Phase 3 STAR trial data for...
